Spots Global Cancer Trial Database for IMM2520, a PD-L1 and CD47 Bispecific Antibody in Patients With Advanced Solid Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: IMM2520, a PD-L1 and CD47 Bispecific Antibody in Patients With Advanced Solid Tumors
Official Title: A Phase 1 Clinical Study to Evaluate IMM2520 Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity in Patients With Advanced Solid Tumors
Study ID: NCT05780307
Interventions
Study Description
Brief Summary: This is a multi-center, open-label, dose-escalation and cohort-expansion phase I clinical study to evaluate the safety and tolerability, pharmacokinetics profile, efficacy and immunogenicity of IMM2520 in subjects with advanced solid tumors.
Detailed Description: IMM2520 is administered via intravenous infusion once week of cycle 1- 12 (4 weeks per cycle). The accelerated titration method and the traditional "3+3" method will be adopted to determine the maximum tolerated dose (MTD) and the recommended phase II dose (RP2D) in dose-escalation phase. Once the RP2D is determined, Simon's two-stage design will be used to explore for each specific tumor cohort.adenocarcinoma/esophageal cancer, urothelial cancer, and/or others.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Affilated Cancer Hospital of Shandong First Medical University, Jinan, Shandong, China
Contact Details
Name: YIXUAN YANG, MD
Affiliation: Clinical Development
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
